Literature DB >> 26998524

Mitochondrial protein hyperacetylation in the failing heart.

Julie L Horton1, Ola J Martin1, Ling Lai1, Nicholas M Riley2, Alicia L Richards2, Rick B Vega1, Teresa C Leone1, David J Pagliarini3, Deborah M Muoio4, Kenneth C Bedi5, Kenneth B Margulies5, Joshua J Coon6, Daniel P Kelly1.   

Abstract

Myocardial fuel and energy metabolic derangements contribute to the pathogenesis of heart failure. Recent evidence implicates posttranslational mechanisms in the energy metabolic disturbances that contribute to the pathogenesis of heart failure. We hypothesized that accumulation of metabolite intermediates of fuel oxidation pathways drives posttranslational modifications of mitochondrial proteins during the development of heart failure. Myocardial acetylproteomics demonstrated extensive mitochondrial protein lysine hyperacetylation in the early stages of heart failure in well-defined mouse models and the in end-stage failing human heart. To determine the functional impact of increased mitochondrial protein acetylation, we focused on succinate dehydrogenase A (SDHA), a critical component of both the tricarboxylic acid (TCA) cycle and respiratory complex II. An acetyl-mimetic mutation targeting an SDHA lysine residue shown to be hyperacetylated in the failing human heart reduced catalytic function and reduced complex II-driven respiration. These results identify alterations in mitochondrial acetyl-CoA homeostasis as a potential driver of the development of energy metabolic derangements that contribute to heart failure.

Entities:  

Year:  2016        PMID: 26998524      PMCID: PMC4795836          DOI: 10.1172/jci.insight.84897

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  64 in total

1.  Open mass spectrometry search algorithm.

Authors:  Lewis Y Geer; Sanford P Markey; Jeffrey A Kowalak; Lukas Wagner; Ming Xu; Dawn M Maynard; Xiaoyu Yang; Wenyao Shi; Stephen H Bryant
Journal:  J Proteome Res       Date:  2004 Sep-Oct       Impact factor: 4.466

2.  Proteomic and phosphoproteomic comparison of human ES and iPS cells.

Authors:  Douglas H Phanstiel; Justin Brumbaugh; Craig D Wenger; Shulan Tian; Mitchell D Probasco; Derek J Bailey; Danielle L Swaney; Mark A Tervo; Jennifer M Bolin; Victor Ruotti; Ron Stewart; James A Thomson; Joshua J Coon
Journal:  Nat Methods       Date:  2011-09-11       Impact factor: 28.547

3.  Mammalian succinate dehydrogenase.

Authors:  B A Ackrell; E B Kearney; T P Singer
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

4.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

Review 5.  Complex II deficiency--a case report and review of the literature.

Authors:  Shailly Jain-Ghai; Jessie M Cameron; Almundher Al Maawali; Susan Blaser; Nevena MacKay; Brian Robinson; Julian Raiman
Journal:  Am J Med Genet A       Date:  2013-01-15       Impact factor: 2.802

Review 6.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

7.  A mitochondrial protein compendium elucidates complex I disease biology.

Authors:  David J Pagliarini; Sarah E Calvo; Betty Chang; Sunil A Sheth; Scott B Vafai; Shao-En Ong; Geoffrey A Walford; Canny Sugiana; Avihu Boneh; William K Chen; David E Hill; Marc Vidal; James G Evans; David R Thorburn; Steven A Carr; Vamsi K Mootha
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

8.  The creatine kinase system in normal and diseased human myocardium.

Authors:  J S Ingwall; M F Kramer; M A Fifer; B H Lorell; R Shemin; W Grossman; P D Allen
Journal:  N Engl J Med       Date:  1985-10-24       Impact factor: 91.245

9.  The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload.

Authors:  Janice M Huss; Ken-ichi Imahashi; Catherine R Dufour; Carla J Weinheimer; Michael Courtois; Atilla Kovacs; Vincent Giguère; Elizabeth Murphy; Daniel P Kelly
Journal:  Cell Metab       Date:  2007-07       Impact factor: 27.287

10.  The Failing Heart Relies on Ketone Bodies as a Fuel.

Authors:  Gregory Aubert; Ola J Martin; Julie L Horton; Ling Lai; Rick B Vega; Teresa C Leone; Timothy Koves; Stephen J Gardell; Marcus Krüger; Charles L Hoppel; E Douglas Lewandowski; Peter A Crawford; Deborah M Muoio; Daniel P Kelly
Journal:  Circulation       Date:  2016-01-27       Impact factor: 29.690

View more
  72 in total

1.  Extracellular signal-regulated kinase 1/2 regulates NAD metabolism during acute kidney injury through microRNA-34a-mediated NAMPT expression.

Authors:  Justin B Collier; Rick G Schnellmann
Journal:  Cell Mol Life Sci       Date:  2019-12-23       Impact factor: 9.261

Review 2.  The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.

Authors:  Samantha S Romanick; Bradley S Ferguson
Journal:  Future Med Chem       Date:  2019-06-04       Impact factor: 3.808

3.  Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.

Authors:  Junco S Warren; Christopher M Tracy; Mickey R Miller; Aman Makaju; Marta W Szulik; Shin-Ichi Oka; Tatiana N Yuzyuk; James E Cox; Anil Kumar; Bucky K Lozier; Li Wang; June García Llana; Amira D Sabry; Keiko M Cawley; Dane W Barton; Yong Hwan Han; Sihem Boudina; Oliver Fiehn; Haley O Tucker; Alexey V Zaitsev; Sarah Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

4.  NAD(H) in mitochondrial energy transduction: implications for health and disease.

Authors:  Matthew A Walker; Rong Tian
Journal:  Curr Opin Physiol       Date:  2018-04-11

Review 5.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

Review 6.  Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.

Authors:  Maggie P Y Lam; Peipei Ping; Elizabeth Murphy
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

7.  Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model.

Authors:  Angelical S Martin; Dennis M Abraham; Kathleen A Hershberger; Dhaval P Bhatt; Lan Mao; Huaxia Cui; Juan Liu; Xiaojing Liu; Michael J Muehlbauer; Paul A Grimsrud; Jason W Locasale; R Mark Payne; Matthew D Hirschey
Journal:  JCI Insight       Date:  2017-07-20

Review 8.  Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases.

Authors:  Alice E Kane; David A Sinclair
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

Review 9.  Disruption of energy utilization in diabetic cardiomyopathy; a mini review.

Authors:  Shinsuke Nirengi; Carmem Peres Valgas da Silva; Kristin I Stanford
Journal:  Curr Opin Pharmacol       Date:  2020-09-25       Impact factor: 5.547

10.  Ablation of Sirtuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload.

Authors:  Kathleen A Hershberger; Dennis M Abraham; Juan Liu; Jason W Locasale; Paul A Grimsrud; Matthew D Hirschey
Journal:  J Biol Chem       Date:  2018-05-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.